Botanical species · safety record

Datura innoxia

The EFSA Compendium of Botanicals holds 21 constituent measurements and 2 adverse-effect records for Datura innoxia. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Datura innoxia Mill.

21Constituent measurements
2Safety records
7Cited sources
0Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Atropine9
  • Scopolamine9
  • Cardiac glycosides1
  • Saponins1
  • Tropane alkaloids1

Plant parts

  • Leaves7
  • Live plants7
  • Flower6
  • Stem2
  • stalk2
  • Roots and other underground parts1

Preparations

  • Solvent extraction15
  • Thermal treatment (heating for preservation)3

Effect types

  • Neurotoxicity2

Target tissues

  • Neurologic: central nervous system2

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AtropineLive plantsSolvent extraction≤ 1330 Microgram/gramGelpermeation, High Performance Thin Layer Chromatography (HPTLC)Resolve DOI
AtropineLive plantsSolvent extraction≥ 60 Microgram/gramGelpermeation, High Performance Thin Layer Chromatography (HPTLC)Resolve DOI
ScopolamineLive plantsSolvent extraction≤ 4000 Microgram/gramGelpermeation, High Performance Thin Layer Chromatography (HPTLC)Resolve DOI
ScopolamineLive plantsSolvent extraction≥ 60 Microgram/gramGelpermeation, High Performance Thin Layer Chromatography (HPTLC)Resolve DOI
AtropineStem / stalkSolvent extraction0.4 Milligram/gramLC-MSNo resolvable identifier
AtropineLeavesThermal treatment (heating for preservation)0.8 Microgram/gramGC-MSNo resolvable identifier
AtropineFlowerSolvent extraction0.03 Milligram/gramLC-MSNo resolvable identifier
AtropineFlower≥ 1.79 Microgram/millilitreLC-MSNo resolvable identifier
AtropineFlower≤ 37 Microgram/millilitreLC-MSNo resolvable identifier
AtropineLeavesSolvent extraction≥ 0.02 Milligram/gramLC-MSNo resolvable identifier
AtropineLeavesSolvent extraction≤ 0.06 Milligram/gramLC-MSNo resolvable identifier
Cardiac glycosidesLive plantsSolvent extractionPhytochemical screeningNo resolvable identifier
SaponinsLive plantsSolvent extractionPhytochemical screeningNo resolvable identifier
ScopolamineFlowerSolvent extraction3.94 Milligram/gramLC-MSNo resolvable identifier
ScopolamineStem / stalkSolvent extraction1.95 Milligram/gramLC-MSNo resolvable identifier
ScopolamineLeavesThermal treatment (heating for preservation)1.2 Microgram/gramGC-MSNo resolvable identifier
ScopolamineLeavesSolvent extraction≤ 4.53 Milligram/gramLC-MSNo resolvable identifier
ScopolamineLeavesSolvent extraction≥ 0.94 Milligram/gramLC-MSNo resolvable identifier
ScopolamineFlower≤ 400.04 Microgram/millilitreLC-MSNo resolvable identifier
ScopolamineFlower≥ 57.8 Microgram/millilitreLC-MSNo resolvable identifier
Tropane alkaloidsLive plantsSolvent extractionGC-MSNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
NeurotoxicityNeurologic: central nervous systemRoots and other underground partsHuman (as organism)Case reportResolve DOI
NeurotoxicityNeurologic: central nervous systemLeavesThermal treatment (heating for preservation)Human (as organism)Case reportNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Oniszczuk, A., Waksmundzka-Hajnos, M., Gadzikowska, M., Podgorski, R., Oniszczuk, T. Influence of Sample Preparation Methods on the Quantitation of Selected Tropane Alkaloids from Herb of Datura innoxia Mill. by HPTLC . Acta chromatographica, 2013, vol. 25, no. 3, p. 545-554. DOI
  2. Jakabova, Silvia., Vincze, Lajos., Farkas, Agnes., Kilar, Ferenc., Boros, Borbala., Felinger, Attila. Determination of tropane alkaloids atropine and scopolamine by liquid chromatography-mass spectrometry in plant organs of Datura species. Journal of chromatography a, 2012, vol. 1232, p. 295-301.
  3. Ayuba, V. O., Ojobe, T. O., Ayuba, S. A. Phytochemical and proximate composition of Datura innoxia leaf, seed, stem, pod and root. Journal of medicinal plants research, 2011, vol. 5, no. 14, p. 2952-2955.
  4. Papoutsis, Ioannis., Nikolaou, Panagiota., Athanaselis, Sotirios., Stefanidou, Maria., Pistos, Constantinos., Spiliopoulou, Chara., Maravelias, Constantinos. Mass intoxication with Datura innoxia-case series and confirmation by analytical toxicology. Clinical toxicology, 2010, vol. 48, no. 2, p. 143-145.
  5. HANNA, JP., SCHMIDLEY, JW., BRASELTON, WE. DATURA DELIRIUM. Clinical neuropharmacology, 1992, vol. 15, no. 2, p. 109-113. DOI
  6. Boros, Borbala., Farkas, Agnes., Jakabova, Silvia., Bacskay, Ivett., Kilar, Ferenc., Felinger, Attila. LC-MS Quantitative Determination of Atropine and Scopolamine in the Floral Nectar of Datura Species. Chromatographia, 2010, vol. 71(Suppl.), p. S43-S49.
  7. El Bazaoui, Ahmed., Bellimam, My Ahmed., Soulaymani, Abdelmajid. Tropane alkaloids of Datura innoxia from Morocco. Zeitschrift fuer naturforschung, c: journal of biosciences, 2012, vol. 67(1/2), p. 8-14.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue